Niagen Bioscience, Inc.: insider trades · United States · SEC (Form 4)

About Niagen Bioscience, Inc.

Niagen Bioscience, Inc. (NASDAQ: NAGE) is a U.S.-based biosciences company headquartered in Los Angeles, California, United States. The company originated as ChromaDex and adopted its current name on March 19, 2025, reflecting a strategic shift toward NAD+ science and healthy aging. Its business has been built around Niagen®, a patented form of nicotinamide riboside (NR), a precursor to NAD+ that the company positions as a scientifically validated ingredient for cellular metabolism and longevity-related applications. Niagen Bioscience now presents itself as a science-led company combining intellectual property, research collaborations, and commercialization of evidence-based products. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2025/ChromaDex-Evolves-Into-Niagen-Bioscience-Marking-a-New-Era-of-Uncovering-the-Potential-of-NAD-With-Precision-Science/default.aspx?utm_source=openai)) The company’s model is organized around three main activities. First is consumer health, led by Tru Niagen®, its flagship oral supplement brand. Second is the ingredients segment, which supplies food-grade and pharmaceutical-grade Niagen® to third-party manufacturers and, in the pharmaceutical channel, to authorized 503B outsourcing facilities. Third is the analytical reference standards and services business, a legacy activity that the company is now strategically exiting through the announced sale of substantially all of those assets. This divestiture underscores a clear focus on NAD+ science, IP monetization, and commercial growth in the longevity sector. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000013/cdxc-20251231.htm?utm_source=openai)) From a competitive standpoint, Niagen Bioscience differentiates itself through a science-heavy brand, a broad patent portfolio around NR, and an extensive global research network. The company describes Tru Niagen as the leading NAD+ boosting oral supplement in the United States based on revenue data from the major U.S. e-commerce marketplace for the referenced period. It also aims to deepen its platform through higher-value formats such as Niagen IV and injectable products, which broadens the commercial opportunity beyond the core supplement business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/pressreleasedatedoctober62.htm?utm_source=openai)) Recent news has emphasized both product expansion and scientific validation. Niagen Bioscience launched Tru Niagen Beauty and, in 2026, introduced a Niagen Skincare Innovation Lab and the limited-release Niagen NanoCloud™ topical product, extending the Niagen ingredient story into skincare. The company has also highlighted clinical and research milestones in long COVID, Parkinson’s disease, and external research agreements, reinforcing its positioning as a platform that converts scientific credibility into commercial optionality. Geographically, the group operates from the United States but has an international footprint through research partnerships, product distribution, and global collaborations. For investors, the stock combines consumer health exposure, a healthy-aging thesis, and a NASDAQ-listed scientific growth story. ([investors.niagenbioscience.com](https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-Launches-Niagen-Skincare-Innovation-Lab-and-Debuts-Dermatologist-Tested-Niagen-NanoCloud-From-Tru-Niagen-Powered-by-Patented-Niagen/default.aspx?utm_source=openai))